Hu, Y., Yang, R., Liu, X., Mei, H., Zhou, H., Wang, S., Huang, R., Wang, Y., Du, X., Sun, J., Zhou, Z., Yan, Z., Chen, W., Wang, W., Liu, Q., Zeng, Q., Gong, Y., Yin, J., Shen, X., Ye, B., Chen, Y., Xu, Y., Sun, H., Cheng, Y., Liu, Z., Wang, C., Yuan, G., Zhang, X., Li, X., Cheng, P., Guo, X., Jiang, Z., Yang, F., Yang, L., Luo, C., Xiao, T., Yin, H., Guo, X., Luo, X., Fan, S., Shi, M. M., Su, W. (2025). Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia. Blood. https://doi.org/10.1182/blood-2025-843